Diagnosis community-acquired pneumonia in emergency unit

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

EU CTR

Registry ID

EUCTR2012-002093-31-FI

Enrollment

Registered

2012-05-02

Start date

2012-05-03

Completion date

Unknown

Last updated

2019-11-25

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

lower respiratory tract infection and pneumonia

Interventions

Trade Name: Avelox Pharmaceutical Form: INN or Proposed INN: MOXIFLOXACIN CAS Number: 151096-09-2

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Are the trial subjects under 18? no Number of subjects for this age range: F.1.2 Adults (18-64 years) yes F.1.2.1 Number of subjects for this age range 80 F.1.3 Elderly (>=65 years) no F.1.3.1 Number of subjects for this age range

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Main Objective: To identify surrogat markes to identify community-acquired pneumonia among adultpatients having lower respiratory tract infection;Secondary Objective: ;Primary end point(s):	—

Countries

Finland

Contacts

Public ContactHospital

Oulu University Hospital

hannu.syrjala@ppshp.fi3588315 3582

Outcome results

None listed

Source: EU CTR (via WHO ICTRP) · Data processed: Feb 4, 2026